hydrochlorothiazide has been researched along with Aging in 36 studies
Hydrochlorothiazide: A thiazide diuretic often considered the prototypical member of this class. It reduces the reabsorption of electrolytes from the renal tubules. This results in increased excretion of water and electrolytes, including sodium, potassium, chloride, and magnesium. It is used in the treatment of several disorders including edema, hypertension, diabetes insipidus, and hypoparathyroidism.
hydrochlorothiazide : A benzothiadiazine that is 3,4-dihydro-2H-1,2,4-benzothiadiazine 1,1-dioxide substituted by a chloro group at position 6 and a sulfonamide at 7. It is diuretic used for the treatment of hypertension and congestive heart failure.
Aging: The gradual irreversible changes in structure and function of an organism that occur as a result of the passage of time.
| Excerpt | Relevance | Reference |
|---|---|---|
| " placebo added to hydrochlorothiazide (HCTZ) for the treatment of essential hypertension." | 9.05 | Labetalol and hydrochlorothiazide in hypertension. Labetalol/Hydrochlorothiazide Multicenter Study Group. ( , 1985) |
| "An open-label clinical trail comparing the effectiveness of the combination of methyldopa with hydrochlorothiazide in low doses with that of hydrochlorothiazide therapy alone was conducted in 21 elderly patients with isolated systolic hypertension." | 7.67 | Hydrochlorothiazide plus methyldopa in the treatment of isolated systolic hypertension in the elderly. ( Boyles, PW, 1984) |
| "This study in patients with moderate-to-severe hypertension assessed the efficacy and safety of adding hydrochlorothiazide (HCTZ) 12." | 5.16 | Efficacy and safety of triple antihypertensive therapy with the olmesartan/amlodipine/hydrochlorothiazide combination. ( Ammentorp, B; Christian Rump, L; Laeis, P; Volpe, M, 2012) |
| " placebo added to hydrochlorothiazide (HCTZ) for the treatment of essential hypertension." | 5.05 | Labetalol and hydrochlorothiazide in hypertension. Labetalol/Hydrochlorothiazide Multicenter Study Group. ( , 1985) |
| "103 patients with arterial hypertension were treated with timolol + placebo for 7 weeks in a multicentre trial, and with timolol + hydrochlorothiazide and amiloride for a further 7-week period." | 5.04 | Individual factors influencing the response to a beta-adrenergic blocking agent given alone and in combination with a diuretic on arterial hypertension. ( Mikkelsen, E; Pedersen, OL, 1979) |
| "An open-label clinical trail comparing the effectiveness of the combination of methyldopa with hydrochlorothiazide in low doses with that of hydrochlorothiazide therapy alone was conducted in 21 elderly patients with isolated systolic hypertension." | 3.67 | Hydrochlorothiazide plus methyldopa in the treatment of isolated systolic hypertension in the elderly. ( Boyles, PW, 1984) |
| "In this study we compared the absorption and disposition of two commonly used combination formulations of hydrochlorothiazide and triamterene (Dyazide and Maxzide) in 48 patients with essential hypertension after dosing with each formulation to steady state." | 3.67 | Absorption and disposition of two combination formulations of hydrochlorothiazide and triamterene: influence of age and renal function. ( Benet, LZ; Blume, C; Clark, TS; Lin, E; Thornhill, MD; Upton, RA; Williams, RL, 1986) |
| " Similar differences have been reported for such patient groups when the drugs were administered separately, indicating an absence of pharmacokinetic interaction." | 2.67 | The effects of age and renal impairment on the pharmacokinetics of co-administered lisinopril and hydrochlorothiazide. ( Connell, PA; Hosie, J; Laher, MS; Mulkerrins, E; Smith, RP; Swaisland, AJ, 1991) |
| "Oxprenolol was well tolerated in the elderly; it produced a low incidence of typical beta-blocker side effects even when given in a once-daily regimen." | 2.65 | Clinical responses to oxprenolol in the elderly. ( Ellis, RA, 1983) |
| "Treatment with furosemide or HCTZ did not have relevant effects on measured parameters." | 1.43 | The Effects of Early Postnatal Diuretics Treatment on Kidney Development and Long-Term Kidney Function in Wistar Rats. ( Bueters, RR; Florquin, S; Jeronimus-Klaasen, A; Maicas, N; Schreuder, MF; van den Heuvel, LP, 2016) |
| " Furthermore, the pharmacodynamic action of diuretics was not significantly altered in the elderly." | 1.30 | Renal handling of drugs in the healthy elderly. Creatinine clearance underestimates renal function and pharmacokinetics remain virtually unchanged. ( Bischoff, I; Block, S; Fliser, D; Hanses, A; Joest, M; Mutschler, E; Ritz, E, 1999) |
| " As a result of the pharmacokinetic findings caution may be indicated in the clinical dosage of the diuretics particularly when in fixed dose combination." | 1.28 | The pharmacokinetics of amiloride-hydrochlorothiazide combination in the young and elderly. ( Ismail, Z; Parke, W; Smithurst, BA; Triggs, EJ, 1989) |
| " No difference in any of the drug pharmacokinetic parameters could be detected between the hypertensives and the normal elderly subjects." | 1.27 | A comparative study of the pharmacokinetics and pharmacodynamics of atenolol, hydrochlorothiazide and amiloride in normal young and elderly subjects and elderly hypertensive patients. ( Adam, HK; Castleden, CM; Fitzsimons, TJ; Ryan, J; Sabanathan, K, 1987) |
| "Now that the benefits of treating diastolic hypertension in the elderly have been convincingly proved, attention is turning to the need for, and the choice of, treatment of isolated systolic hypertension in this age group." | 1.27 | Management of isolated systolic hypertension in the elderly. ( Gifford, RW, 1986) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 13 (36.11) | 18.7374 |
| 1990's | 12 (33.33) | 18.2507 |
| 2000's | 7 (19.44) | 29.6817 |
| 2010's | 4 (11.11) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Heng, YK | 1 |
| Lim, YL | 1 |
| Bueters, RR | 1 |
| Jeronimus-Klaasen, A | 1 |
| Maicas, N | 1 |
| Florquin, S | 1 |
| van den Heuvel, LP | 1 |
| Schreuder, MF | 1 |
| Tiwari, S | 1 |
| Li, L | 1 |
| Riazi, S | 1 |
| Halagappa, VK | 1 |
| Ecelbarger, CM | 1 |
| Hannan, JL | 2 |
| Blaser, MC | 1 |
| Pang, JJ | 1 |
| Adams, SM | 1 |
| Pang, SC | 1 |
| Adams, MA | 2 |
| Volpe, M | 1 |
| Christian Rump, L | 1 |
| Ammentorp, B | 1 |
| Laeis, P | 1 |
| Werner, H | 1 |
| Grant, RW | 1 |
| Singer, DE | 1 |
| Meigs, JB | 1 |
| Demirci, B | 1 |
| McKeown, PP | 1 |
| Bayraktutan, U | 1 |
| Smallegange, C | 1 |
| Hale, TM | 1 |
| Heaton, JP | 1 |
| Palmieri, V | 1 |
| Pini, R | 1 |
| Chiara Cavallini, M | 1 |
| Hall, CE | 1 |
| Holland, OB | 1 |
| Hall, O | 1 |
| Ellis, RA | 1 |
| Boyles, PW | 1 |
| Amery, A | 3 |
| Birkenhäger, W | 3 |
| Bulpitt, C | 2 |
| Clement, D | 2 |
| Deruyttere, M | 2 |
| De Schaepdryver, A | 2 |
| Dollery, C | 2 |
| Fagard, R | 3 |
| Forette, F | 3 |
| Forte, J | 2 |
| Hamdy, R | 1 |
| Leonetti, G | 1 |
| Lund-Johansen, P | 2 |
| MacFarlane, JP | 1 |
| Mutsers, A | 2 |
| O'Malley, K | 1 |
| Tuomilehto, J | 2 |
| Schraeger, JA | 1 |
| Canby, CA | 1 |
| Rongish, BJ | 1 |
| Kawai, M | 1 |
| Tomanek, RJ | 1 |
| Ljungman, S | 1 |
| Wikstrand, J | 1 |
| Hartford, M | 1 |
| Aurell, M | 1 |
| Lindstedt, G | 1 |
| Berglund, G | 1 |
| Slovick, DI | 1 |
| Bulpitt, CJ | 1 |
| Cox, J | 1 |
| de Leeuw, P | 1 |
| de Cort, P | 1 |
| Fletcher, A | 1 |
| Traub, O | 1 |
| Lloyd, MC | 1 |
| Webb, RC | 1 |
| Frohlich, ED | 1 |
| Conlin, PR | 1 |
| Elkins, M | 1 |
| Liss, C | 1 |
| Vrecenak, AJ | 1 |
| Barr, E | 1 |
| Edelman, JM | 1 |
| Fliser, D | 1 |
| Bischoff, I | 1 |
| Hanses, A | 1 |
| Block, S | 1 |
| Joest, M | 1 |
| Ritz, E | 1 |
| Mutschler, E | 1 |
| Giummelly, P | 1 |
| Lartaud-Idjouadiene, I | 1 |
| Marque, V | 1 |
| Niederhoffer, N | 1 |
| Chillon, JM | 1 |
| Capdeville-Atkinson, C | 1 |
| Atkinson, J | 1 |
| Louis, WJ | 1 |
| Mander, AG | 1 |
| Dawson, M | 1 |
| O'Callaghan, C | 1 |
| Conway, EL | 1 |
| Goto, K | 1 |
| Fujii, K | 1 |
| Onaka, U | 1 |
| Abe, I | 1 |
| Fujishima, M | 1 |
| Berthaux, P | 1 |
| Boel, A | 1 |
| Brixko, P | 1 |
| De Padua, F | 1 |
| Henry, JF | 1 |
| Hellemans, J | 1 |
| Koistinen, A | 1 |
| Laaser, U | 1 |
| MacFarlane, J | 1 |
| Miguel, P | 1 |
| Nissinen, A | 1 |
| Ohm, OT | 1 |
| Pelemans, W | 1 |
| Suchett-Kaye, AI | 1 |
| Willems, J | 1 |
| Willemse, P | 1 |
| Pedersen, OL | 1 |
| Mikkelsen, E | 1 |
| Laher, MS | 1 |
| Mulkerrins, E | 1 |
| Hosie, J | 1 |
| Connell, PA | 1 |
| Smith, RP | 1 |
| Swaisland, AJ | 1 |
| Djian, J | 1 |
| Roy, M | 1 |
| Forette, B | 1 |
| Lekieffre, J | 1 |
| Luccioni, R | 1 |
| Materson, BJ | 1 |
| Cushman, WC | 1 |
| Goldstein, G | 1 |
| Reda, DJ | 1 |
| Freis, ED | 2 |
| Ramirez, EA | 1 |
| Talmers, FN | 1 |
| White, TJ | 1 |
| Nunn, S | 1 |
| Chapman, RH | 1 |
| Cummings, DM | 1 |
| Amadio, P | 1 |
| Taylor, EJ | 1 |
| Balaban, DJ | 1 |
| Rocci, ML | 1 |
| Abrams, WB | 1 |
| Feinberg, J | 1 |
| Vlasses, PH | 1 |
| Ismail, Z | 1 |
| Triggs, EJ | 1 |
| Smithurst, BA | 1 |
| Parke, W | 1 |
| Sabanathan, K | 1 |
| Castleden, CM | 1 |
| Adam, HK | 1 |
| Ryan, J | 1 |
| Fitzsimons, TJ | 1 |
| Williams, RL | 1 |
| Thornhill, MD | 1 |
| Upton, RA | 1 |
| Blume, C | 1 |
| Clark, TS | 1 |
| Lin, E | 1 |
| Benet, LZ | 1 |
| Gifford, RW | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Randomised, Double-Blind, Parallel-Group Study Evaluating Efficacy and Safety of Co-Administration of Triple Combinations of Olmesartan Medoxomil, Amlodipine Besylate, and Hydrochlorothiazide Compared With Corresponding Olmesartan - Amlodipine Combination[NCT00923091] | Phase 3 | 2,689 participants (Actual) | Interventional | 2009-06-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Baseline blood pressure was defined as the average values obtained at the randomization visit and at the visit prior to randomization (NCT00923091)
Timeframe: Baseline to week 10
| Intervention | mm HG (Least Squares Mean) |
|---|---|
| Olmesartan/Amlodipine/Hydrochlorothiazide 20mg/5mg/12.5 mg | -22.5 |
| Olmesartan/Amlodipine/Hydrochlorothiazide 40mg/5mg/12.5mg | -22.5 |
| Olmesartan/Amlodipine/Hydrochlorothiazide 40mg/5mg/25mg | -23.0 |
| Olmesartan/Amlodipine/Hydrochlorothiazide 40mg/10mg/12.5mg | -23.9 |
| Olmesartan/Amlodipine/Hydrochlorothiazide 40mg/10mg/25mg | -23.8 |
| Olmesartan/Amlodipine 20mg/5mg | -20.5 |
| Olmesartan/Amlodipine 40mg/5mg | -21.2 |
| Olmesartan/Amlodipine 40mg/10mg | -22.1 |
(NCT00923091)
Timeframe: Week 18 to week 22
| Intervention | mm Hg (Least Squares Mean) |
|---|---|
| Olmesartan/Amlodipine/Hydrochlorothiazide 20mg/5mg/12.5 mg | -3.3 |
| Olmesartan/Amlodipine/Hydrochlorothiazide 40mg/5mg/12.5mg | -4.1 |
(NCT00923091)
Timeframe: Week 22 to week 26
| Intervention | mm Hg (Least Squares Mean) |
|---|---|
| OLM/AML/HCTZ 40/5/12.5mg Nonresponders Randomized to 40/5/12.5 | -2.7 |
| OLM/AML/HCTZ 40/5/12.5mg Nonresponders Randomized to 40/5/25 | -3.8 |
(NCT00923091)
Timeframe: Week 26 to week 54
| Intervention | mm Hg (Mean) |
|---|---|
| OLM/AML/HCTZ 40/5/25 Titrated to 40/10/25 | -11.9 |
(NCT00923091)
Timeframe: Baseline to week 10
| Intervention | mm Hg (Least Squares Mean) |
|---|---|
| Olmesartan/Amlodipine/Hydrochlorothiazide 20mg/5mg/12.5 mg | -33.2 |
| Olmesartan/Amlodipine/Hydrochlorothiazide 40mg/5mg/12.5mg | -33.7 |
| Olmesartan/Amlodipine/Hydrochlorothiazide 40mg/5mg/25mg | -35.3 |
| Olmesartan/Amlodipine/Hydrochlorothiazide 40mg/10mg/12.5mg | -35.5 |
| Olmesartan/Amlodipine/Hydrochlorothiazide 40mg/10mg/25mg | -36.2 |
| Olmesartan/Amlodipine 20mg/5mg | -29.9 |
| Olmesartan/Amlodipine 40mg/5mg | -30.4 |
| Olmesartan/Amlodipine 40mg/10mg | -32.8 |
(NCT00923091)
Timeframe: Week 18 to week 22
| Intervention | mm Hg (Least Squares Mean) |
|---|---|
| Olmesartan/Amlodipine/Hydrochlorothiazide 20mg/5mg/12.5 mg | -5.7 |
| Olmesartan/Amlodipine/Hydrochlorothiazide 40mg/5mg/12.5mg | -6.5 |
(NCT00923091)
Timeframe: Week 22 to week 26
| Intervention | mm Hg (Least Squares Mean) |
|---|---|
| OLM/AML/HCTZ 40/5/12.5mg Nonresponders Randomized to 40/5/12.5 | -4.5 |
| OLM/AML/HCTZ40/5/12.5mg Nonresponders Randomized to 40/5/25 | -6.7 |
Blood pressure treatment goal was defined as blood pressure <140/90 mmHg or <130/80 mmHg for subjects with diabetes, chronic renal disease, or chronic cardiovascular disease. (NCT00923091)
Timeframe: baseline to week 10
| Intervention | Participants (Number) |
|---|---|
| Olmesartan/Amlodipine/Hydrochlorothiazide 20mg/5mg/12.5 mg | 177 |
| Olmesartan/Amlodipine/Hydrochlorothiazide 40mg/5mg/12.5mg | 176 |
| Olmesartan/Amlodipine/Hydrochlorothiazide 40mg/5mg/25mg | 197 |
| Olmesartan/Amlodipine/Hydrochlorothiazide 40mg/10mg/12.5mg | 190 |
| Olmesartan/Amlodipine/Hydrochlorothiazide 40mg/10mg/25mg | 179 |
| Olmesartan/Amlodipine 20mg/5mg | 144 |
| Olmesartan/Amlodipine 40mg/5mg | 155 |
| Olmesartan/Amlodipine 40mg/10mg | 166 |
Blood pressure treatment goal was defined as blood pressure <140/90 mmHg or <130/80 mmHg for subjects with diabetes, chronic renal disease, or chronic cardiovascular disease. (NCT00923091)
Timeframe: Week 22 to week 26
| Intervention | Participants (Number) |
|---|---|
| OLM/AML/HCTZ 40/5/12.5mg Nonresponders Randomized to 40/5/12.5 | 29 |
| OLM/AML/HCTZ 40/5/12.5mg Nonresponders Randomized to 40/5/25 | 47 |
Blood pressure treatment goal was defined as blood pressure <140/90 mmHg or <130/80 mmHg for subjects with diabetes, chronic renal disease, or chronic cardiovascular disease. (NCT00923091)
Timeframe: Week 18 to week 22
| Intervention | Participants (Number) |
|---|---|
| Olmesartan/Amlodipine/Hydrochlorothiazide 20mg/5mg/12.5 mg | 63 |
| Olmesartan/Amlodipine/Hydrochlorothiazide 40mg/5mg/12.5mg | 137 |
1 review available for hydrochlorothiazide and Aging
| Article | Year |
|---|---|
Cutaneous adverse drug reactions in the elderly.
Topics: Aged; Aged, 80 and over; Aging; Calcium Channel Blockers; Humans; Hydrochlorothiazide; Neoplasms; Pr | 2015 |
12 trials available for hydrochlorothiazide and Aging
| Article | Year |
|---|---|
Efficacy and safety of triple antihypertensive therapy with the olmesartan/amlodipine/hydrochlorothiazide combination.
Topics: Adult; Aged; Aging; Amlodipine; Antihypertensive Agents; Double-Blind Method; Drug Therapy, Combinat | 2012 |
Clinical responses to oxprenolol in the elderly.
Topics: Aged; Aging; Clinical Trials as Topic; Drug Therapy, Combination; Drug Tolerance; Humans; Hydrochlor | 1983 |
Influence of anti-hypertensive therapy on serum cholesterol in elderly hypertensive patients. Results of trial by the European Working Party on High blood pressure in the Elderly (EWPHE).
Topics: Aged; Aging; Blood Pressure; Cholesterol; Clinical Trials as Topic; Europe; Female; Follow-Up Studie | 1982 |
SYST-EUR multicentre trial on the treatment of isolated systolic hypertension in the elderly: first interim report.
Topics: Aged; Aging; Blood Pressure; Circadian Rhythm; Cognition; Dementia, Vascular; Double-Blind Method; D | 1993 |
A study of losartan, alone or with hydrochlorothiazide vs nifedipine GITS in elderly patients with diastolic hypertension.
Topics: Aged; Aging; Antihypertensive Agents; Calcium Channel Blockers; Diastole; Double-Blind Method; Drug | 1998 |
Use of computerized neuropsychological tests (CANTAB) to assess cognitive effects of antihypertensive drugs in the elderly. Cambridge Neuropsychological Test Automated Battery.
Topics: Aged; Aging; Antihypertensive Agents; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Cogniti | 1999 |
Antihypertensive therapy in patients above age 60 years (Fourth Interim report of the European Working Party on High Blood pressure in Elderly: EWPHE).
Topics: Aged; Aging; Blood Glucose; Blood Pressure; Body Weight; Clinical Trials as Topic; Creatinine; Doubl | 1978 |
Individual factors influencing the response to a beta-adrenergic blocking agent given alone and in combination with a diuretic on arterial hypertension.
Topics: Adult; Aging; Amiloride; Body Weight; Clinical Trials as Topic; Drug Therapy, Combination; Heart Rat | 1979 |
The effects of age and renal impairment on the pharmacokinetics of co-administered lisinopril and hydrochlorothiazide.
Topics: Adult; Aged; Aged, 80 and over; Aging; Angiotensin-Converting Enzyme Inhibitors; Blood Pressure; Dru | 1991 |
Efficacy and tolerance of sustained-release diltiazem 300 mg and a diuretic in the elderly.
Topics: Aged; Aging; Blood Pressure; Delayed-Action Preparations; Diltiazem; Drug Tolerance; Female; Heart R | 1990 |
Treatment of hypertension in the elderly: I. Blood pressure and clinical changes. Results of a Department of Veterans Affairs Cooperative Study.
Topics: Aged; Aging; Antihypertensive Agents; Blood Pressure; Diuretics; Drug Administration Schedule; Drug | 1990 |
Labetalol and hydrochlorothiazide in hypertension. Labetalol/Hydrochlorothiazide Multicenter Study Group.
Topics: Administration, Oral; Adult; Aged; Aging; Analysis of Variance; Blood Pressure; Clinical Trials as T | 1985 |
23 other studies available for hydrochlorothiazide and Aging
| Article | Year |
|---|---|
The Effects of Early Postnatal Diuretics Treatment on Kidney Development and Long-Term Kidney Function in Wistar Rats.
Topics: Acute-Phase Proteins; Aging; Animals; Apoptosis; Blood Pressure; Body Weight; Cell Proliferation; Di | 2016 |
Sex and age result in differential regulation of the renal thiazide-sensitive NaCl cotransporter and the epithelial sodium channel in angiotensin II-infused mice.
Topics: Age Factors; Aging; Angiotensin II; Animals; Blood Pressure; Diuretics; Epithelial Sodium Channels; | 2009 |
Impact of hypertension, aging, and antihypertensive treatment on the morphology of the pudendal artery.
Topics: Age Factors; Aging; Animals; Antihypertensive Agents; Apomorphine; Enalapril; Endothelium, Vascular; | 2011 |
[Lethal polypharmacy in a patient with arterial hypertension--re the article from DMW 50/2004].
Topics: Age Factors; Aged; Aged, 80 and over; Aging; Angiotensin-Converting Enzyme Inhibitors; Antihypertens | 2005 |
Medication adherence before an increase in antihypertensive therapy: a cohort study using pharmacy claims data.
Topics: Adult; Aging; Antihypertensive Agents; Atenolol; Case-Control Studies; Cohort Studies; Drug Prescrip | 2005 |
Blockade of angiotensin II provides additional benefits in hypertension- and ageing-related cardiac and vascular dysfunctions beyond its blood pressure-lowering effects.
Topics: Aging; Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Aorta, Thoracic; B | 2005 |
Impact of antihypertensive treatments on erectile responses in aging spontaneously hypertensive rats.
Topics: Aging; Animals; Antihypertensive Agents; Apomorphine; Blood Pressure; Enalapril; Hydralazine; Hydroc | 2006 |
Pulsology reloaded: commentary on similar effects of treatment on central and brachial blood pressure in older hypertensive subjects.
Topics: Aged; Aged, 80 and over; Aging; Amlodipine; Antihypertensive Agents; Atenolol; Blood Pressure; Brach | 2007 |
Evolution of adrenal regeneration hypertension in rats with actively regenerating or fully regenerated glands.
Topics: Adrenal Glands; Aging; Animals; Blood Pressure; Body Weight; Diet; Drinking; Female; Heart; Hydrochl | 1967 |
Hydrochlorothiazide plus methyldopa in the treatment of isolated systolic hypertension in the elderly.
Topics: Aged; Aging; Blood Pressure; Drug Therapy, Combination; Female; Humans; Hydrochlorothiazide; Hyperte | 1984 |
Normal left ventricular diastolic compliance after regression of hypertrophy.
Topics: Aging; Animals; Blood Pressure; Body Weight; Captopril; Cardiomegaly; Collagen; Diastole; Elasticity | 1994 |
Effects of long-term antihypertensive treatment and aging on renal function and albumin excretion in primary hypertension.
Topics: Aging; Albuminuria; Case-Control Studies; Drug Therapy, Combination; Follow-Up Studies; Glomerular F | 1993 |
Long-term effects of brief antihypertensive treatment on systolic blood pressure and vascular reactivity in young genetically hypertensive rats.
Topics: Aging; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Agents; B | 1995 |
Arthus C. Corcoran Memorial Lecture. Influence of nitric oxide and angiotensin II on renal involvement in hypertension.
Topics: Aging; Angiotensin-Converting Enzyme Inhibitors; Animals; Disease Models, Animal; Diuretics; Endothe | 1997 |
Renal handling of drugs in the healthy elderly. Creatinine clearance underestimates renal function and pharmacokinetics remain virtually unchanged.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aging; Atenolol; Creatinine; Diuretics; Female; Glomerular | 1999 |
Effects of aging and antihypertensive treatment on aortic internal diameter in spontaneously hypertensive rats.
Topics: Age Factors; Aging; Analysis of Variance; Angiotensin-Converting Enzyme Inhibitors; Animals; Antihyp | 1999 |
Angiotensin-converting enzyme inhibitor prevents age-related endothelial dysfunction.
Topics: Acetylcholine; Administration, Oral; Aging; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors | 2000 |
The antihypertensive response to lisinopril: the effect of age in a predominantly black population.
Topics: Adult; Aged; Aged, 80 and over; Aging; Aldosterone; Angiotensin-Converting Enzyme Inhibitors; Black | 1989 |
The pharmacokinetics of amiloride-hydrochlorothiazide combination in the young and elderly.
Topics: Adult; Aged; Aging; Amiloride; Drug Combinations; Female; Humans; Hydrochlorothiazide; Male | 1989 |
Age and antihypertensive drugs (hydrochlorothiazide, bendroflumethiazide, nadolol and captopril).
Topics: Adult; Aged; Aging; Bendroflumethiazide; Black People; Blood Pressure; Captopril; Dose-Response Rela | 1988 |
A comparative study of the pharmacokinetics and pharmacodynamics of atenolol, hydrochlorothiazide and amiloride in normal young and elderly subjects and elderly hypertensive patients.
Topics: Adult; Aged; Aging; Amiloride; Atenolol; Blood Pressure; Drug Combinations; Heart Rate; Humans; Hydr | 1987 |
Absorption and disposition of two combination formulations of hydrochlorothiazide and triamterene: influence of age and renal function.
Topics: Absorption; Adult; Aged; Aging; Biological Availability; Creatinine; Humans; Hydrochlorothiazide; Hy | 1986 |
Management of isolated systolic hypertension in the elderly.
Topics: Adult; Aged; Aging; Antihypertensive Agents; Aorta, Thoracic; Blood Pressure; Cardiac Output; Hemody | 1986 |